Alzheimer's Target and the Treatment Progression of Classic and New Clinical Drugs

Author:

Chen Hankun,Wang Tingyang

Abstract

Alzheimer’s Disease (AD) is a traditional neurodegeneration disease in the world. In 1906, this disease is first described by German Neuroscientist, Alois Alzheimer, and it is named by this scientist, ‘Alzheimer’. Although 4-5% of patient carry AD at middle age, which is the Early- onset Alzheimer’s Disease. Normally, the average onset age of AD is above 65. The symptom of AD including dementia, loss of memory, cognitive impairment and eventually it will accelerate the death of aged people. There are two pathological factors that cause people have AD’s symptom: Amyloid Plaques and Neurofibrillary Tangles (NFTs). Focus on that, this review will mainly introduce two medicine treatments that target those two factors: The classical cholinergic medicine Donepezil and The Novel Lithium medicine that has been proved to treat AD since 2012. This article will describe the pathology of AD briefly; focus on those two medicines, the functional mechanism, effectiveness to AD and limitation will be described also.

Publisher

Darcy & Roy Press Co. Ltd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3